Business News • PR NewsWire • Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial

SHANGHAI and SYDNEY , March 2, 2016 /PRNewswire/ -- WuXi Biologics Co. Ltd., a wholly owned subsidiary of WuXi AppTec Co. Ltd. (WuXi), and Prima BioMed Ltd. (Prima) (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company, announced today that through their...

View More : http://www.prnewswire.com/news-releases/prima-biomed-and-wuxi-biologics-announce-first-dose-of-chinese-manufactured-biol...

Releted News by prnewswire